Clinical Outcome and Risk Factors for Thoracic Surgery

Dear Colleagues,

The Journal of Clinical Medicine (JCM) is now introducing a Special Issue series that will update our clinical and scientific community on the recent advances in pulmonary medicine. Thoracic surgery has undergone notable changes in recent years. First, the advent of minimally invasive thoracoscopic and robotic surgery techniques revolutionized our surgical practice and had a great impact on both perioperative and long-term results. At the same time, minimal invasiveness has become not only surgical but also the pre-operative and post-operative treatment of patients has changed. Just think of the worldwide implementation of ERAS protocols. We have then entered the era of screening programs for lung cancer, which is bringing excellent results and allows us to send more and more patients to the surgical table with initial lesions and therefore with excellent treatment prospects. In addition to surgery, oncology is also changing; targeted therapies and immunotherapy are revolutionizing the treatment of lung cancer and also our clinical and surgical practice.

To obtain the maximum effect in minimally invasive surgery and to operate on patients undergoing neoadjuvant therapies, especially immunotherapy, correct stratification of surgical risk is essential for us as surgeons. This last aspect today requires a careful multidisciplinary evaluation aimed at evaluating all the respiratory, cardiological, anesthesiologic, internal, rehabilitation, and nutritional aspects that we know significantly influence the post-operative course of our patients.

Finally, the careful evaluation of the long-term results will help us to correctly understand the role of minimally invasive surgery, such as anatomical sublobar pulmonary resections, robotic surgery, hybrid surgery techniques, and thoracic surgery, in immunotreated or subjected patients to targeted therapies and how to obtain the maximum effect in terms of survival by combining surgery with these therapies.

To answer these important questions and promote future research, we sincerely welcome your submissions to this Special Issue of the JCM.

Prof. Dr. Andrea Dell’Amore
Dr. Alessio Campisi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.